Edwards Lifesciences Co. (NYSE:EW) VP Sells $645,620.00 in Stock

Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. sold 9,500 shares of the business’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $67.96, for a total transaction of $645,620.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,189,770.56. The trade was a 16.83 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock opened at $69.37 on Friday. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The stock has a market capitalization of $40.78 billion, a price-to-earnings ratio of 9.95, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The company has a fifty day moving average of $71.74 and a 200-day moving average of $70.33. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Equities research analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Canaccord Genuity Group boosted their target price on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a research note on Thursday, February 13th. Royal Bank of Canada reissued an “outperform” rating and issued a $85.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and boosted their price target for the company from $75.00 to $90.00 in a research report on Thursday, January 30th. Truist Financial reissued a “hold” rating and issued a $78.00 price target (up previously from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Finally, Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and boosted their price target for the company from $82.00 to $90.00 in a research report on Monday, December 16th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $79.95.

Institutional Investors Weigh In On Edwards Lifesciences

A number of institutional investors have recently made changes to their positions in the business. Crowley Wealth Management Inc. purchased a new stake in Edwards Lifesciences during the 4th quarter valued at $26,000. Vega Investment Solutions purchased a new stake in Edwards Lifesciences during the 4th quarter valued at $27,000. Millstone Evans Group LLC purchased a new stake in Edwards Lifesciences during the 4th quarter valued at $29,000. FSA Wealth Management LLC purchased a new stake in Edwards Lifesciences during the 3rd quarter valued at $30,000. Finally, Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Edwards Lifesciences during the 4th quarter valued at $30,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.